Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

The prototyical tumor suppressor p53 is able to arrest cells after DNA damage or as a response to oncogene expression. The transactivation-competent (TA) isoforms of the more recently discovered p53 family member p73 also prevent tumors, but the underlying mechanisms are less well understood. The work presented here addressed this issue by using a cell culture model of tumorigenesis in which normal human diploid fibroblasts are stepwise transduced with oncogenes. Cells in pretransformed stages were shown to harbour high levels of TAp73 mRNA and protein. This positive regulation was probably a result of pRB inactivation and derepression of E2F1, a key activator of TAp73. Consequences for such cells included an increased sensitivity to the cytostatic drug adriamycin, slower proliferation and reduced survival at high cell density, as demonstrated by rescue experiments using siRNA-mediated knockdown of TAp73. In order to identify potential effector pathways, the gene expression profile of siRNA treated, matched fibroblast cell lines with high and low TAp73 levels were compared in DNA microarrays. These findings support the notion of TAp73 up-regulation as an anti-proliferative defense mechanism, blocking the progress towards full transformation. This barrier could be overcome by the introduction of a constitutively active form of Ras which caused a switch from TAp73 to oncogenic DeltaNp73 expression, presumably through the phosphatidylinositol 3-kinase (PI3K) pathway. In summary, the results presented emphasize the tumor-suppressive function of TAp73 and indicate that its downregulation is a decisive event during the transformation of human cells by oncogenic Ras mutants. / Der gut untersuchte Tumorsuppressor p53 vermag das Wachstum von Zellen nach DNA-Schädigung oder Onkogenaktivierung zu arretieren. Die transaktivierungsfähigen (TA) Isoformen von p73, eines kürzlich entdeckten Mitgliedes der p53-Familie, können ebenfalls die Tumorentstehung verhindern. Die Mechanismen sind hier aber noch sehr unvollkommen verstanden. Zu deren Untersuchung wurde in der vorliegenden Arbeit ein Zellkulturmodell der Tumorentstehung verwendet, bei dem normale humane diploide Fibroblasten schrittweise mit bestimmten Onkogenen transduziert wurden. Zellen in unvollständig transformierten Stadien hatten hohe Spiegel an TAp73-mRNA und -Protein. Diese positive Regulation war vermutlich eine Folge von pRB-Inaktivierung und der Derepression von E2F1, einem der wichtigsten Aktivatoren von TAp73. Beobachtete Konsequenzen für solche Zellen waren höhere Empfindlichkeit für Zytostatika wie Adriamycin, langsameres Wachstum und geringere Überlebensfähigkeit bei hoher Zelldichte, was durch Rescue-Experimente mit siRNA-vermitteltem TAp73-Knock down gezeigt werden konnte. Um mögliche Effektor-Signalwege zu identifizieren, wurden die Genexpressionsprofile von siRNA-behandelten Fibroblastenlinien, die sich nur im TAp73-Spiegel unterschieden, in DNA microarrays verglichen. Die Befunde daraus lassen den Schluss zu, dass die Hochregulation von TAp73 einen antiproliferativen Schutzmechanimus darstellt, der die vollständige Transformation verhindert. Diese Barriere konnte überwunden werden durch die zusätzliche Präsenz von aktiviertem Ras, das einen Wechsel der Expression von TAp73 zu der von onkogenem DeltaNp73 bewirkte. Dies ist vermutlich abhängig vom Phosphatidylinositol-Signalweg. Zusammenfassend wurde die Rolle von TAp73 als Tumorsuppressor weiter gefestigt, da die Niederregulierung des Proteins eine zentrale Rolle in der Transformation menschlicher Zellen durch onkogene Ras-Mutanten spielt.

No description available.

No / Although p53 has long been known as the “guardian of the genome” with a role in tumor suppression in many tissues, the discovery of two p53 ancestral genes, p63 and p73, more than a decade ago has triggered a considerable amount of research into the role of these genes in skin development and diseases. In this review, we primarily focus on mechanisms of action of p53 and p63, which are the best-studied p53 family members in the skin. The existence of multiple isoforms and their roles as transcriptional activators and repressors are key to their function in multiple biological processes including the control of skin morphogenesis, regeneration, tumorigenesis, and response to chemotherapy. Last, we provide directions for further research on this family of genes in skin biology and pathology.

No description available.

No description available.

Ph.D. / Molecular and Medical Genetics / The objective of this study is to examine, in light of the expression of multiple p53 family member isoforms, the specific role of p73 in malignant conversion, cellular response to DNA damage, and direct or indirect cooperation with other p53 family members in a clonal model of epidermal carcinogenesis. We first focused on the role of p73 in malignant conversion. Whether sporadic or siRNA induced, loss of p73 in initiated p53+/+ keratinocytes lead to conversion to squamous cell carcinoma (SCC) in vivo which was reversible upon reconstitution of TAp73α but not ΔNp73α. Second, we investigated the cellular response to ionizing radiation (IR) in the presence and absence of p73, showing that loss of p73 at malignant conversion was associated with resistance to IR in vitro. The loss of radiation sensitivity and malignant conversion was characterized by reduced steady state DNA binding levels of transcriptionally active p63 isoforms to the p21 promoter, failure to induce specific p53 family transcriptional targets, and failure to arrest in G1. Reconstitution of TAp73α, but not ΔNp73α, increased steady state DNA binding capabilities of TAp63β, TAp63γ, and ΔNp63γ, and steady state levels of p53 family target mRNA, but did not restore cellular sensitivity to IR. We thus uncovered a functional cooperation between TA isoforms of p73 and p63 and showed that p73-mediated DNA damage response was uncoupled from its tumor suppressive role. We observed preferential DNA binding of the inhibitory ΔNp63α isoform both in vitro and invivo in SCC suggesting that in the absence of TAp73α a balance is tipped toward DNA binding of the inhibitory isoforms. Third, we studied the role of the p53 family inkeratinocyte response to UVB. Tumorigenic cells lacking p73 that were resistant to IR remained sensitive to UVB, accompanied by DNA binding of the TAp63γ isoform, suggesting that keratinocyte response to UVB is not dependent upon p73 and suggesting a hierarchy of p53 family member responses to DNA damage. Finally, we examined TAp73α interaction with the p53 family inhibitor Mdm2. Mdm2 was in complex with DNA-bound p53 family members in malignant cells, but reconstitution of cells withTAp73α correlated with removal of Mdm2 from the complex, making them more like primary keratinocytes or initiated cells. Like the initiated cells, cells expressing TAp73α were refractory to treatment with the Mdm2-p53 inhibitor Nutlin-3 while cells lacking p73 expression or expressing ΔNp73α were sensitive. Thus, we suggest that p73 may be acting as a molecular shield to keep p53 family member inhibitors, such as ΔNp63α andMdm2, at bay. Further understanding of p53 family interplay in tumor development and DNA damage response could lead to new therapies or optimization of current therapeutic strategies in solid tumors of epithelium, particularly where deregulation or loss of p63 and p73 expression is associated with increased tumor invasiveness, treatment resistance, and poor patient prognosis.